Bioidentical hormones vs standard HRT: what is the difference?

Short version

• “Bioidentical” means the hormone molecule is chemically identical to the hormone your body makes (for example, 17β‑estradiol or micronized progesterone).
• “Standard” or conventional HRT usually refers to FDA‑approved products that may be bioidentical (some are) or non‑bioidentical/synthetic (for example conjugated equine estrogens, medroxyprogesterone).
• The main practical differences are source/labeling, regulation, and sometimes route/formulation — not clear evidence that compounded bioidentical preparations are safer or more effective.

What “bioidentical” really means

• Bioidentical hormones have the same molecular structure as endogenous hormones (estradiol, progesterone, testosterone). They are often derived from plant precursors (yams, soy) and then converted in a lab to the same chemical structure as human hormones.
• Important distinction: some FDA‑approved products are bioidentical (for example micronized progesterone and estradiol products). Other products marketed as “bioidentical” are custom‑made (compounded) by pharmacies.

What “standard HRT” covers

• Conventional HRT includes many FDA‑approved options: oral estrogen tablets, transdermal patches/gels, vaginal rings/creams, and progestins. Examples:
  • Estradiol patches: Climara, Vivelle‑Dot (transdermal estradiol) — these deliver 17β‑estradiol (bioidentical) and avoid first‑pass liver metabolism.
  • Estradiol gels: EstroGel, Divigel.
  • Micronized progesterone (bioidentical): Prometrium (oral).
  • Conjugated equine estrogens: Premarin (non‑bioidentical).
  • Medroxyprogesterone acetate: Provera (a synthetic progestin).
• These products are manufactured under FDA regulation for purity, dosing consistency, and required labeling.

Compounded bioidentical hormones

• Compounded bioidentical hormone therapy (CBHT) are tailor‑made formulations from compounding pharmacies and frequently promoted as “natural” and individualized.
• Concerns: variable potency, inconsistent dosing, contamination risk, lack of large randomized trials, and they are not FDA‑approved. Some compounded preparations are reasonable when a patient truly needs a unique dose/form, but they carry more uncertainty.

Safety and effectiveness — what the evidence says

• For menopause symptom relief (hot flashes, vaginal atrophy, etc.), many FDA‑approved estrogen and progestogen options are effective.
• There is no convincing evidence that compounded BHRT is safer or more effective than FDA‑approved HRT.
• Risks associated with hormone therapy depend on type, dose, route, duration, and individual risk factors (age, time since menopause, smoking, clotting disorders, breast cancer risk, cardiovascular disease). Known concerns include increased risk of venous thromboembolism, stroke, and (with some regimens) breast cancer; transdermal estradiol appears to have a lower VTE risk than some oral estrogens.
• Some data suggest micronized (bioidentical) progesterone might have a more favorable risk profile for breast and cardiovascular outcomes than certain synthetic progestins, but evidence is not definitive.

Other practical points

• Delivery route matters: transdermal (patch/gel) avoids first‑pass liver metabolism and may lower clotting and lipid effects compared with oral estrogen.
• Routine saliva hormone testing is unreliable and not recommended for dose adjustment — dosing is based on symptoms and, when needed, blood tests for safety monitoring.
• If you consider compounded BHRT, use an accredited compounding pharmacy (look for USP compliance or Pharmacy Compounding Accreditation Board [PCAB] accreditation), get a clear prescription from a qualified clinician, and have appropriate follow‑up.

What to do next

• Discuss goals, medical history, and risks with a clinician experienced in menopause care (gynecologist, endocrinologist, or menopause specialist). The North American Menopause Society (NAMS) is a good resource.
• If you prefer an FDA‑regulated product, examples to discuss with your clinician: Vivelle‑Dot or Climara (transdermal estradiol), Prometrium (micronized progesterone) for endometrial protection when needed. If you’re offered compounded BHRT, ask why an FDA‑approved option is not suitable and what quality controls the pharmacy uses.

If you want, tell me:

• your age, menopausal status, major medical history (clotting disorder, breast cancer, heart disease), and main symptoms — I can summarize likely safe options to discuss with your clinician.